Bioniche’s Canadian filing for Urocidin delayed
Canadian biopharma firm Bioniche Life Sciences (TSX: BNC) has provided an update on its plans for a New Drug Submission filing in Canada for Urocidin, the company's Phase III bladder cancer product, indicating a six-month delay.
Urocidin is a formulation of MCNA, a sterile mycobacterial cell wall-nucleic acid composition that has anticancer activity. Previously known as MCC suspension, this name has been changed to reflect thedetailed characterization of MCC suspension following receipt of regulatory feedback.
A failure to gain marketing approval for Urocidin could be devastating for the company, which registers about $1.5 million in loses monthly (about $18 million annually) and deemed to be in “precarious financial position” by one dissident shareholder, according to a recent local media report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze